Novo Nordisk reported third quarter 2026 sales of DKK 79,195 million and net income of DKK 16,740 million, raised its full year sales and profit outlook, and cited strong demand for GLP 1 obesity and diabetes treatments, especially the Wegovy pill.
The earnings update showed oral Wegovy rapidly becoming a central product, with management leaning on this momentum while also planning meaningful US list price cuts for Wegovy and Ozempic from January 2027.
We will now look at how Novo Nordisk’s stronger outlook, anchored in Wegovy pill demand, affects the broader investment narrative.
Scan how Novo Nordisk’s GLP 1 momentum compares with other potential breakouts in obesity and metabolic care by reviewing the hand picked 126 healthcare AI stocks list.
Novo Nordisk Investment Narrative Recap
To own Novo Nordisk, you effectively need to believe the GLP 1 engine, led by the Wegovy pill, can offset pricing pressure and any bumps in older diabetes products while capacity ramps. The Q3 picture is mixed but workable. Sales reached DKK 79,195 million with net income of DKK 16,740 million, and guidance moved higher, so the operating story is still anchored in volume growth rather than aggressive pricing.
The main short term catalyst remains execution on oral Wegovy, from supply to payer coverage, as it shoulders more of the growth burden. The biggest risk is that Wegovy pill economics start to resemble the weaker U.S. injectable pricing, compressing margins just as Novo Nordisk commits heavy capital to capacity and a broader GLP 1 pipeline.
The ObesityWeek 2026 data slate is the clearest near term event that ties directly into this earnings story. Novo Nordisk plans 26 obesity portfolio abstracts, including real world Wegovy pill and injection outcomes, plus early looks at CagriSema and pediatric semaglutide. That volume of clinical readouts gives investors fresh information on treatment durability, quality of life and real world adherence.
For you, the interest is simple. Strong, clean data on oral Wegovy and CagriSema would reinforce the idea that current manufacturing expansion and R&D spend are backed by a durable, clinically supported demand base. Weaker or more mixed results would not break the Q3 upgrade on their own but would increase the sense that Novo Nordisk is more exposed to pricing and concentration risk in GLP 1 than the current story implies.
Novo Nordisk’s analyst narrative projects DKK 338.9b revenue and DKK 104.7b earnings by 2029, compared with earnings today of DKK 116.4b. This implies an earnings decrease of DKK 11.7b alongside broadly flat revenue expectations over the period.
Uncover why Novo Nordisk’s fair value indicates a 6% potential upside to its current price, which could narrow quickly.
CPSE:NOVO B 1-Year Stock Price Chart Exploring Other Perspectives
Some of the lowest Novo Nordisk analysts focus on semaglutide price pressure rather than Wegovy pill momentum. Before this Q3 surprise, they were modelling revenue of about DKK 284.0b and earnings near DKK 79.3b by 2029, well below consensus. That is a materially more cautious story. Use this earnings beat as a chance to compare those contrasting paths yourself.
Explore 16 other Novo Nordisk fair value estimates, including one that suggests it could be worth just DKK 287.00.
Decide For Yourself
Don’t just follow the ticker. Dig into the data and build a conviction that’s truly your own.
Looking for more Novo Nordisk sized investment ideas?
If the Novo Nordisk story has sharpened your thinking, use that momentum to widen your opportunity set with a few focused screeners on Simply Wall St.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com